1243 related articles for article (PubMed ID: 31553834)
1. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE; Peyrin-Biroulet L; Loftus EV; Danese S; Colombel JF; Törüner M; Jonaitis L; Abhyankar B; Chen J; Rogers R; Lirio RA; Bornstein JD; Schreiber S;
N Engl J Med; 2019 Sep; 381(13):1215-1226. PubMed ID: 31553834
[TBL] [Abstract][Full Text] [Related]
2. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
Peyrin-Biroulet L; Loftus EV; Colombel JF; Danese S; Rogers R; Bornstein JD; Chen J; Schreiber S; Sands BE; Lirio RA
Gastroenterology; 2021 Oct; 161(4):1156-1167.e3. PubMed ID: 34144047
[TBL] [Abstract][Full Text] [Related]
3. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S
Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Feagan BG; Rutgeerts P; Sands BE; Hanauer S; Colombel JF; Sandborn WJ; Van Assche G; Axler J; Kim HJ; Danese S; Fox I; Milch C; Sankoh S; Wyant T; Xu J; Parikh A;
N Engl J Med; 2013 Aug; 369(8):699-710. PubMed ID: 23964932
[TBL] [Abstract][Full Text] [Related]
6. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants.
Reinisch W; Sandborn WJ; Panaccione R; Huang B; Pollack PF; Lazar A; Thakkar RB
Inflamm Bowel Dis; 2013 Jul; 19(8):1700-9. PubMed ID: 23665965
[TBL] [Abstract][Full Text] [Related]
7. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Sands BE; Sandborn WJ; Panaccione R; O'Brien CD; Zhang H; Johanns J; Adedokun OJ; Li K; Peyrin-Biroulet L; Van Assche G; Danese S; Targan S; Abreu MT; Hisamatsu T; Szapary P; Marano C;
N Engl J Med; 2019 Sep; 381(13):1201-1214. PubMed ID: 31553833
[TBL] [Abstract][Full Text] [Related]
11. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab for the Treatment of Chronic Pouchitis.
Travis S; Silverberg MS; Danese S; Gionchetti P; Löwenberg M; Jairath V; Feagan BG; Bressler B; Ferrante M; Hart A; Lindner D; Escher A; Jones S; Shen B;
N Engl J Med; 2023 Mar; 388(13):1191-1200. PubMed ID: 36988594
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis.
Schultz BG; Diakite I; Carter JA; Snedecor SJ; Turpin R
J Manag Care Spec Pharm; 2021 Nov; 27(11):1592-1600. PubMed ID: 34714104
[No Abstract] [Full Text] [Related]
14. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ;
Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520
[TBL] [Abstract][Full Text] [Related]
17. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab for induction and maintenance of remission in ulcerative colitis.
Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG
Cochrane Database Syst Rev; 2014 Aug; (8):CD007571. PubMed ID: 25105240
[TBL] [Abstract][Full Text] [Related]
19. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
[TBL] [Abstract][Full Text] [Related]
20. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
Colombel JF; Sandborn WJ; Ghosh S; Wolf DC; Panaccione R; Feagan B; Reinisch W; Robinson AM; Lazar A; Kron M; Huang B; Skup M; Thakkar RB
Am J Gastroenterol; 2014 Nov; 109(11):1771-80. PubMed ID: 25155227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
